We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


PolyTherics Receives a Technology Strategy Board Grant to Develop Fusion Proteins

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PolyTherics Receives a Technology Strategy Board Grant to Develop Fusion Proteins"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
PolyTherics Limited has announced that it has started work on a Technology Strategy Board (TSB) funded project to produce fusion proteins using its chemical linker technologies.

PolyTherics will chemically fuse different but complementary proteins using its proprietary polyethylene glycol (PEG) linkers. The goal of the project is to develop a way of fusing proteins that is both quicker and cheaper than producing a fusion protein using recombinant techniques whilst retaining the different functions of both proteins. This will allow for rapid generation of a range of new fusion proteins for screening for a range of uses in a variety of industries, including as potential therapeutic products.

As PolyTherics’ PEGylation technologies enable the PEG to be attached to a specific site on a protein, either on the histidine residues added to facilitate its purification, or at a naturally occurring disulfide, the effect of the PEG on the function of the protein can be minimized. In addition, PEG is known to protect proteins from breakdown by proteases and thus improve their stability, a potential advantage over recombinant fusion proteins.